77.08
7.49 (10.76%)
| Penutupan Terdahulu | 69.59 |
| Buka | 70.60 |
| Jumlah Dagangan | 1,233,388 |
| Purata Dagangan (3B) | 1,066,787 |
| Modal Pasaran | 2,298,721,536 |
| Harga / Pendapatan (P/E Ke hadapan) | 243.90 |
| Harga / Jualan (P/S) | 4.96 |
| Harga / Buku (P/B) | 9.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Oct 2026 |
| Margin Keuntungan | -11.69% |
| Margin Operasi (TTM) | -5.22% |
| EPS Cair (TTM) | -1.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 39.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 44.61% |
| Nisbah Semasa (MRQ) | 3.25 |
| Aliran Tunai Operasi (OCF TTM) | -1.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 17.79 M |
| Pulangan Atas Aset (ROA TTM) | -1.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | GeneDx Holdings Corp. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 12.56% |
| % Dimiliki oleh Institusi | 102.71% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Oracle Investment Management Inc | 31 Dec 2025 | 884,654 |
| Zweig-Dimenna Associates Llc | 31 Mar 2026 | 689,290 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |